Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:42 PM
Ignite Modification Date:
2025-12-24 @ 12:42 PM
NCT ID:
NCT00005861
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed stage III, IV, or recurrent endometrial carcinoma for which curative radiotherapy or surgery is not an option
* Bidimensionally measurable disease
* Irradiated field as only site allowed if evidence of progression since radiotherapy
PATIENT CHARACTERISTICS:
Age:
* Not specified
Performance status:
* GOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic:
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* SGOT no greater than 3 times ULN
* Alkaline phosphatase no greater than 3 times ULN
Renal:
* Creatinine no greater than 1.5 times ULN
Cardiovascular:
* LVEF normal by cardiac echocardiogram or MUGA
Other:
* No concurrent active infection
* No prior or concurrent malignancy within past 5 years except nonmelanoma skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* Prior chemotherapy as radiosensitizer allowed
* No prior chemotherapy for advanced or metastatic disease
* No other concurrent chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* See Disease Characteristics
* Recovered from prior radiotherapy
Surgery:
* See Disease Characteristics
* Recovered from prior surgery
Other:
* No prior therapy that would preclude study
* No other concurrent antineoplastic agents
* No other concurrent investigational agents
Healthy Volunteers:
False
Sex:
FEMALE
Study:
NCT00005861
Study Brief:
Protocol Section:
NCT00005861